Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Wolfgang Oster"'
Autor:
Varun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, Lanlan Zhou, Marie Ralff, Jocelyn Ray, Aakash Jhaveri, Isacco Ferrarini, Young Lee, Cassandra Parker, Yiqun Zhang, Robyn Borsuk, Wen-I Chang, Joshua N. Honeyman, Fabio Tavora, Benedito Carneiro, Alexander Raufi, Kelsey Huntington, Lindsey Carlsen, Anna Louie, Howard Safran, Attila A. Seyhan, Rohinton S. Tarapore, Lee Schalop, Martin Stogniew, Joshua E. Allen, Wolfgang Oster, Wafik S. El-Deiry
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agon
Externí odkaz:
https://doaj.org/article/ab2136215d2b48418947dffdd2998a3e
Autor:
Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human tri
Externí odkaz:
https://doaj.org/article/cc2e3e6b70b34104941a2588a1bfa557
Autor:
Wafik S. El-Deiry, Wolfgang Oster, Varun V. Prabhu, David T. Dicker, Bora Lim, Jessica Wagner, Ozan C. Küçükkase, Christina L.B. Kline, Marie D. Ralff
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f19ace8fa9940e522f089595f42822a
https://doi.org/10.1158/1535-7163.22510656.v1
https://doi.org/10.1158/1535-7163.22510656.v1
Autor:
Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor, Isabel Arrillaga-Romany, Robert Wechsler-Reya, Jessica Rusert, Mark R. Gilbert, Deric M. Park, Jinkyu Jung, Neil Charter, Sean Deacon, Rohinton S. Tarapore, Jessica Durrant, Alexander VanEngelenburg, Faye Doherty, Olivier Elemento, Wafik S. El-Deiry, Sophie Oster, C. Leah B. Kline, Coryandar Gilvary, Neel S. Madhukar, Varun V. Prabhu
Figure S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e308d507bf1d92c73420b66051a502d5
https://doi.org/10.1158/1078-0432.22472331
https://doi.org/10.1158/1078-0432.22472331
Autor:
Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor, Isabel Arrillaga-Romany, Robert Wechsler-Reya, Jessica Rusert, Mark R. Gilbert, Deric M. Park, Jinkyu Jung, Neil Charter, Sean Deacon, Rohinton S. Tarapore, Jessica Durrant, Alexander VanEngelenburg, Faye Doherty, Olivier Elemento, Wafik S. El-Deiry, Sophie Oster, C. Leah B. Kline, Coryandar Gilvary, Neel S. Madhukar, Varun V. Prabhu
Purpose:Dopamine receptor D2 (DRD2) is a G protein–coupled receptor antagonized by ONC201, an anticancer small molecule in clinical trials for high-grade gliomas and other malignancies. DRD5 is a dopamine receptor family member that opposes DRD2 si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5247f7654a50fe6322025926a51c4f46
https://doi.org/10.1158/1078-0432.c.6528195
https://doi.org/10.1158/1078-0432.c.6528195
Autor:
Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor, Isabel Arrillaga-Romany, Robert Wechsler-Reya, Jessica Rusert, Mark R. Gilbert, Deric M. Park, Jinkyu Jung, Neil Charter, Sean Deacon, Rohinton S. Tarapore, Jessica Durrant, Alexander VanEngelenburg, Faye Doherty, Olivier Elemento, Wafik S. El-Deiry, Sophie Oster, C. Leah B. Kline, Coryandar Gilvary, Neel S. Madhukar, Varun V. Prabhu
Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86181d49990cf8948bf53f9c5827dffc
https://doi.org/10.1158/1078-0432.22472319
https://doi.org/10.1158/1078-0432.22472319
Autor:
Janice M. Mehnert, Wolfgang Oster, Martin Stogniew, Joshua E. Allen, Wafik S. El-Deiry, Ling Zheng, Siobhan Dickerson, Christian Gabel, Saltanat Najmi, Bangning Yu, Yasmeen Beckett, Sherri Damare, Andrew Zloza, Tracie Saunders, Robert S. DiPaola, Bruce G. Haffty, Robert D. Aiken, Joseph Aisner, Lorna Rodriguez, Jyoti Malhotra, Nancy Chan, Ann Silk, Rebecca Moss, Tina Mayer, Howard L. Kaufman, Joseph R. Bertino, Mark N. Stein
'Figure S1: ONC201 doses versus (A) Cmax and (B) AUC determined after the first dose of ONC201.; Figure S2: Covariant analyses of pharmacokinetic parameters; Figure S3: Caspase-cleaved versus total cytokeratin 18 at baseline and 21 days following the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5886082eddc07eb452d92a2c8685f3d8
https://doi.org/10.1158/1078-0432.22468470.v1
https://doi.org/10.1158/1078-0432.22468470.v1
Autor:
Janice M. Mehnert, Wolfgang Oster, Martin Stogniew, Joshua E. Allen, Wafik S. El-Deiry, Ling Zheng, Siobhan Dickerson, Christian Gabel, Saltanat Najmi, Bangning Yu, Yasmeen Beckett, Sherri Damare, Andrew Zloza, Tracie Saunders, Robert S. DiPaola, Bruce G. Haffty, Robert D. Aiken, Joseph Aisner, Lorna Rodriguez, Jyoti Malhotra, Nancy Chan, Ann Silk, Rebecca Moss, Tina Mayer, Howard L. Kaufman, Joseph R. Bertino, Mark N. Stein
Purpose: ONC201 is a small-molecule selective antagonist of the G protein–coupled receptor DRD2 that is the founding member of the imipridone class of compounds. A first-in-human phase I study of ONC201 was conducted to determine its recommended ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07de6f5e685558bcce25aecdcab42022
https://doi.org/10.1158/1078-0432.c.6526959
https://doi.org/10.1158/1078-0432.c.6526959
Autor:
Joshua E. Allen, Wolfgang Oster, Patrick Y. Wen, Tracy T. Batchelor, Isabel Arrillaga-Romany, Robert Wechsler-Reya, Jessica Rusert, Mark R. Gilbert, Deric M. Park, Jinkyu Jung, Neil Charter, Sean Deacon, Rohinton S. Tarapore, Jessica Durrant, Alexander VanEngelenburg, Faye Doherty, Olivier Elemento, Wafik S. El-Deiry, Sophie Oster, C. Leah B. Kline, Coryandar Gilvary, Neel S. Madhukar, Varun V. Prabhu
Supplementary legends for Figures S1-S5 and Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1862ccddb1e46f633458f1fcb1dfb754
https://doi.org/10.1158/1078-0432.22472322.v1
https://doi.org/10.1158/1078-0432.22472322.v1
Autor:
Marie D. Ralff, Benedito A. Carneiro, Lanlan Zhou, Wen-I Chang, Rohinton Tarapore, Varun V. Prabhu, Joshua N. Honeyman, Attila A. Seyhan, Isacco Ferrarini, Alexander G. Raufi, Lindsey Carlsen, Martin Stogniew, Lee Schalop, Robyn Borsuk, Joshua E. Allen, Aakash Jhaveri, Cassandra Parker, Sara Morrow, Young Lee, Fabio Tavora, Wolfgang Oster, Jocelyn E. Ray, Kelsey E. Huntington, Howard Safran, Anna D Louie, Abed Rahman Kawakibi, Yiqun Zhang, Wafik S. El-Deiry
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agon